Evaluation of in-vitro Immunomodulatory Activity and Thrombolytic Potential of Kabasura Kudineer (KSK): An Official Siddha Polyherbal Formulation

Abstract:

Aim: Coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), attacking mainly on the immune system of a body. This has spread mortality and morbidity all over the world. During this dreadful situation there is an urgent need for the development and rapid dissemination of COVID-19 treatment. Siddha’s traditional medicine system can be used as preventive care to boost the immune system. Materials and Methods: The immense treasure of knowledge found in Siddha medicine can help mortality. Kabasura Kudineer (KSK) is one of the Siddha poly herbal formulation used as an immune-boosting agent against several diseases. Results: In the present study the KSK has been investigated for its effects of immunomodulatory and thrombolytic potential. The KSK at the concentrations of 12.5, 25, 50, and 100 μg/ml showed % immune-stimulations of 12.40 %, 20.81, 33.53, and 43.20 and for NBT showed 19.00, 25.50, 64.00, 71.00 % respectively. Moreover, similarly, the thrombolytic activity showed 50, and 100 μg/ml concentration showed 43.83 %, 71.83 % clot lysis, respectively, and the control value for the Streptokinase showed 83.78 %. Conclusion: Hence, it can be confirmed that KSK has immunomodulatory and thrombolytic properties in vitro models. Immunomodulatory and anti-thrombolytic are the steps to create a stable, safe, and efficient COVID-19 cure.

Key words: Kabasura Kudineer (KSK), Immunomodulatory, Thrombolytic, COVID-19, Siddha formulation.